This page covers public companies that use computational chemistry, physics-based simulation, AI-enabled biology, biosimulation, or antibody design to turn models into drug candidates, partner packages, regulated development workflows, milestones, royalties, or owned clinical assets. The node gets paid only when a customer pays for software or services, a partner accepts a program, a milestone or option exercise brings cash, or a platform-originated asset produces human evidence. The current basket read is that SDGR has the cleanest paid computational-design signal, RXRX has the purest TechBio operating-system exposure, CERT adds paid biosimulation workflow evidence, ABCL and RLAY still depend on clinical conversion, and ABSI needs ABS-201 data plus partner economics before its AI-antibody story is more than option value.
What the stack is: computational design platforms are software, data, automated biology, chemistry, and modeling systems that predict, design, test, and refine drug candidates before or during wet-lab and clinical development.
What it does: the stack narrows molecule search space, models binding and dose behavior, generates antibody or small-molecule candidates, runs virtual and physical experiments, and packages evidence that partners, regulators, or internal clinical teams can use.
Main operating pieces: physics-based molecular simulation, AI models, proprietary biology maps, automated labs, biosimulation engines, model-informed drug development tools, antibody discovery workflows, clinical assets, partner contracts, milestone schedules, and cash runway.
Where it sits: these systems sit inside discovery software subscriptions, pharma and biotech R&D workflows, automated wet labs, biosimulation teams, partner discovery packages, and company-owned clinical pipelines.
How the theme uses it: AI-enabled biology needs proof that models reduce experimental work, improve candidate quality, support regulatory or clinical decisions, and convert into revenue, gross margin, milestone cash, royalties, or proprietary asset value.
Terms used later: ACV means annual contract value for software customers; TechBio means an integrated technology-and-biology operating platform; model-informed drug development means using quantitative models to guide dose, trial, and regulatory decisions; downstream participation means milestones, royalties, equity, or other economics after a partner advances a program.
Report boundary: this node is a tactical report layer. It ranks the current value-chain basket, confirmation triggers, invalidation checks, and chart provenance. Durable research, claim IDs, raw source registries, and sector thesis maintenance stay in the linked knowledge pages. Price and volume context comes from read-only discovery daily_ohlc through 2026-06-12.
Current Setup
Paid platform proofSoftware and partner cash matter more than model claims.
SDGR and CERT already show paid workflow demand; RXRX, ABCL, RLAY, and ABSI need clinical, partner, or dilution evidence to turn platform output into investable economics.
Positive proofACV, bookings, and accepted programs are the cleaner signals.
Watch SDGR ACV, CERT bookings, RXRX partner milestones, and ABCL635 or ABS-201 data.
Conversion gateModel output must become cash, margin, or human evidence.
Revenue quality, milestones, option exercises, and runway decide whether platform value accrues to shareholders.
Primary constraintBurn, lumpy revenue, and clinical concentration raise the cash-to-data hurdle.
Do not treat price strength as platform validation without same-window operating evidence.
Input layerModels, data, wet lab
Buyer routePharma, biotech, internal R&D
Cash routeACV, services, milestones
Proof pointHuman data + runway
Computational design is the highest-purity public route to the AI-biology theme, but the proof is not a benchmark or a model demo. The usable evidence is paid software ACV, hosted platform adoption, biosimulation bookings, partner package acceptance, milestone receipts, option exercises, cash runway, and human data that show model output can survive wet-lab, clinical, and regulatory gates. SDGR and CERT are paid workflow validators; RXRX, ABCL, RLAY, and ABSI carry more direct platform or clinical optionality but need data, partner cash, and dilution discipline.
Pharma, biotech, and regulated development customers are funding computational tools where they shorten design cycles, improve dose and trial decisions, or create partner-ready discovery packages. SDGR has the clearest current payment route through software ACV and hosted adoption; RXRX has the broadest public TechBio system after adding Exscientia; CERT is already paid for biosimulation and model-informed drug development; ABCL and RLAY have near-term clinical evidence windows that can prove platform-origin assets matter; ABSI has a clean ABS-201 catalyst calendar. The next positive proof is software and services revenue that holds, milestones or option exercises that bring cash, and human data that support a credible regulatory path.
The node can fail even if the science improves. Collaboration revenue can stay lumpy, clinical programs can miss, software gross margin can stay under pressure, and equity-funded runway can raise the per-share hurdle before the platform is validated. CERT also overlaps with the Clinical Translation And Evidence Rails node, while RLAY is now more zovegalisib clinical asset exposure than reusable platform revenue. Watch SDGR ACV and margin, RXRX ATM use and REC-4881 timing, CERT post-divestiture bridge, ABCL635 data, RLAY offering absorption and follow-up data, and ABS-201 safety, PK, proof-of-concept, and partner economics.
Right-rail charts load weekly bars from the report API; the local daily_ohlc store was checked through 2026-06-12 for all six tickers. Fundamental claims route to the AI biology platform validation concept page, Health Care sector lane, funding dependency concept page, and linked security lanes.
Basket
This basket is inherited from the parent theme, reviewed against the AI biology platform validation concept page, checked with current company releases, and ranked by source-backed node economics first, platform purity second, and technical timing last. The six ranked U.S. tickers already have local discovery and knowledge coverage. EXAI is excluded because Exscientia is now inside Recursion; SLP, 2228.HK, 3696.HK, and private leaders remain source-trail comparables until local chart and knowledge coverage supports them.
Market cap uses the 2026-06-12 local adjusted close multiplied by the discovery instrument weighted share count. Next earnings dates are marked Not confirmed because Nasdaq earnings pages returned no current date and no future Q2 2026 earnings event was found on the checked company IR materials as of 2026-06-13.
Best paid computational-design signal because software ACV, hosted adoption, and collaboration economics are disclosed.
Market cap$1.08B
Next earningsNot confirmed
Latest qtr revenue$58.6M
Role in stack
Pharma, biotech, materials, and internal drug-discovery teams use SDGR software and physics-based simulation to design molecules. Theme pressure converts through ACV, hosted usage, renewals, partner milestones, and equity or downstream economics from co-discovered assets.
Revenue mix
Q1 2026 revenue was software products and services $35.6M, drug discovery $22.9M, and contribution revenue $0.1M. Software is the cleaner recurring workflow route; drug discovery validates the platform but is lumpy.
Latest qtr revenue
Q1 2026 total revenue was $58.6M for the quarter ended March 31, 2026, from the company release dated May 5, 2026.
Purest public TechBio operating-system exposure, but current revenue is not yet a self-funding base.
Market cap$1.67B
Next earningsNot confirmed
Latest qtr revenue$6.5M
Role in stack
Recursion combines scaled biology, chemistry, imaging, compute, automated labs, and Exscientia assets. Partners and internal programs convert the platform into economics only when packages, milestones, option exercises, regulatory-path clarity, or clinical assets offset fixed platform cost.
Revenue mix
Q1 2026 revenue was $6.3M operating revenue plus $0.2M grant revenue. It is collaboration and research-service evidence, not product revenue or enough cash generation to fund the platform.
Latest qtr revenue
Q1 2026 total revenue was $6.472M for the quarter ended March 31, 2026, from the company release dated May 8, 2026.
Paid biosimulation and model-informed drug development workflow with clearer current economics than most platform peers.
Market cap$0.80B
Next earningsNot confirmed
Latest qtr revenue$106.9M
Role in stack
Biopharma, biotech, academic, government, and regulatory customers use CERT software and services to model dose, trial, and regulatory decisions. Conversion comes through software bookings, renewals, services stabilization, adjusted EBITDA, and cash conversion.
Revenue mix
Q1 2026 revenue was $49.7M software and $57.2M services. Software grew 7% year over year while services declined 4%, so the setup depends on software holding and services stabilizing after the divestiture.
Latest qtr revenue
Q1 2026 total revenue was $106.9M for the quarter ended March 31, 2026, from the company release dated May 11, 2026.
Cash-backed antibody platform route where ABCL635 and partner downstreams must prove repeatability.
Market cap$1.60B
Next earningsNot confirmed
Latest qtr revenue$8.3M
Role in stack
AbCellera uses antibody-discovery technology, GPCR and ion-channel biology, partner programs, and internal clinical development to create proprietary assets, milestones, royalties, and out-license value.
Revenue mix
Revenue is research fees, licensing, milestones, royalties, and partner-led downstream participation in a single reportable segment. Q1 revenue is too small to fund the operating base, so liquidity and ABCL635 evidence matter more.
Latest qtr revenue
Q1 2026 total revenue was $8.3M for the quarter ended March 31, 2026, from the company release dated May 6, 2026.
Motion-based computational-design platform with the clearest human-efficacy read-through but single-asset concentration.
Market cap$2.84B
Next earningsNot confirmed
Latest qtr revenue$3.0M
Role in stack
Relay uses Dynamo and motion-based design to develop precision oncology assets. Conversion is now asset-specific: ReDiscover-2, ReInspire durability, triplet regulatory feedback, and eventual product or partnership value decide the economics.
Revenue mix
Relay is a development-stage pipeline company with no product revenue. Q1 2026 revenue came from the Elevar license agreement; current value depends on zovegalisib clinical and regulatory evidence rather than recurring platform revenue.
Latest qtr revenue
Q1 2026 revenue was $3.0M for the quarter ended March 31, 2026, from the company release dated May 5, 2026.
AI-plus-wet-lab antibody option where ABS-201 and partner economics must validate the platform.
Market cap$1.06B
Next earningsNot confirmed
Latest qtr revenue$0.2M
Role in stack
Absci applies generative AI and wet-lab antibody design to ABS-201, ABS-202, and partnered programs. Conversion requires human safety, pharmacokinetics, proof-of-concept data, and disclosed pharma economics that reduce dilution pressure.
Revenue mix
Revenue is minimal partner-program revenue, not product sales. The company says it is advancing partnered discussions, but current economics depend on clinical data and non-dilutive deal terms becoming visible.
Latest qtr revenue
Q1 2026 revenue was $0.2M for the quarter ended March 31, 2026, from the company release dated May 7, 2026.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
1Node thesisPlatform validation
What confirms
Paid software, hosted platform use, biosimulation revenue, partnerships, milestones, option exercises, and human data show computational design is becoming a budgeted workflow.
What weakens or invalidates
Platform stories depend mainly on equity funding, model benchmarks, press releases, or one clinical asset without recurring customer adoption or cash evidence.
Watch next
SDGR ACV
CERT software mix
RXRX partner milestones
ABCL635
ABS-201
2Economics mechanismCash conversion
What confirms
Recurring software, services, milestones, royalties, option exercises, or owned-pipeline economics convert model outputs into revenue, margin, cash flow, or partner funding.
What weakens or invalidates
Revenue stays lumpy, cash burn rises, partner demand slows, services weakness spreads, or KPI changes reduce comparability across periods.
Watch next
Q2/Q3 revenue mix
Software gross margin
Bookings
Adjusted EBITDA
Operating cash use
3Customer evidenceBuyer adoption
What confirms
Pharma, biotech, and regulated development customers renew software, expand hosted usage, buy biosimulation work, accept discovery packages, or exercise options on platform-originated programs.
What weakens or invalidates
Customer-budget pressure shows up in lower ACV, weak software bookings, delayed partner milestones, fewer accepted packages, or reduced downstream participation.
Watch next
SDGR hosted adoption
CERT services bookings
Roche/Genentech milestones
AbCellera downstreams
4FundingRunway and dilution
What confirms
Cash runway extends through key readouts without depressed-price issuance, and partner cash or software cash flow reduces the need for equity funding.
What weakens or invalidates
ATM use, follow-on issuance, rising burn, or weak partner cash inflows raise the per-share cash and data hurdle before validation arrives.
Watch next
RXRX ATM use
RLAY share count
ABSI runway
ABCL liquidity
SDGR burn
5Policy and operating gatesClinical and regulatory
What confirms
Model-informed development tools, FDA interactions, clean safety/PK, clinical efficacy, and partner-accepted packages show that computational output survives regulated development gates.
What weakens or invalidates
Clinical misses, regulatory delays, weak dose evidence, services execution problems, or software gross-margin pressure dilute the claim that the platform improves development productivity.
Watch next
REC-4881 path
REC-617 safety/PK
ABCL635 Phase 2
Zovegalisib follow-up
ABS-201 data
6Stale conditionRefresh trigger
What confirms
Knowledge lanes, company releases, local daily_ohlc, and chart metadata are refreshed together before new claims or tickers are added.
What weakens or invalidates
Missing local chart or knowledge coverage forces unsupported peer additions, stale clinical claims, or unchartable basket names.
Next earnings dates were searched on 2026-06-13 using Nasdaq earnings pages for SDGR, RXRX, CERT, ABCL, RLAY, and ABSI and checked against the linked company IR materials. Nasdaq returned no current earnings date for the six tickers, and the company materials reviewed showed past Q1 2026 calls rather than future Q2 2026 dates, so every Basket card uses Not confirmed.
Market-cap tiles use local discovery instrument weighted shares outstanding multiplied by the 2026-06-12 adjusted close from daily_ohlc: SDGR 74.7M shares at $14.45, RXRX 530.8M at $3.15, CERT 153.3M at $5.20, ABCL 305.3M at $5.24, RLAY 191.6M at $14.81, and ABSI 155.9M at $6.80. Rounded market caps are shown in the Basket cards.
Latest-quarter revenue uses company-reported Q1 2026 total revenue for the quarter ended March 31, 2026: SDGR $58.6M, RXRX $6.472M, CERT $106.9M, ABCL $8.3M, RLAY $3.0M, and ABSI $0.2M. Segment or revenue-mix notes are in each card's Revenue mix section.
Discovery And Chart Provenance
Read-only discovery checks used discovery status TICKER --json for SDGR, RXRX, CERT, ABCL, RLAY, and ABSI. All six had daily_ohlc coverage through 2026-06-12 and enough bars for three-year weekly charts and 100-week EMA calculations.
Read-only DuckDB checked daily_ohlc latest dates, row counts, latest closes, and market-cap inputs for the six tickers. Weekly chart aggregation uses first open, maximum high, minimum low, final close, and summed volume by calendar week.
Indicators use weekly closes to compute 20-week and 100-week EMAs. The visible chart horizon is three years, with full available weekly history used before visible-window clipping. Current article-body setup thresholds were removed; selected-security charts and setup labels belong in the right rail and API metadata.
Right-rail charts load at runtime from /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest. The node does not embed full OHLC payloads in HTML.
Local 13F holdings were empty for all six tickers in discovery status, so this page does not make holder-concentration claims.
Review validation confirmed static API hooks and metadata. A live loopback HTTP chart probe may remain environment-limited if the local report API is not reachable at 127.0.0.1:8765.
Known Gaps
Lineage status for recent daily_ohlc updates shows older ticker-specific ingestion runs for several names even though stored OHLC coverage extends to 2026-06-12; the next discovery maintenance pass should reconcile lineage metadata.
No confirmed next earnings dates were found in the bounded checks, so earnings-date tiles should be refreshed before using this page for near-term event timing.
SLP, 2228.HK, 3696.HK, and private companies such as Isomorphic Labs, Xaira, Chai, EvolutionaryScale, Benchling, and TetraScience remain comparables, not ranked basket names, because this report lacks local chart and security-lane coverage for them.
CERT overlaps with the Clinical Translation And Evidence Rails node; this page keeps it only as a paid biosimulation and MIDD workflow validator.
RLAY has the strongest current human evidence in the group, but it is mostly zovegalisib clinical-asset exposure rather than recurring platform revenue.
Shared parent and sitemap freshness metadata were left deferred by review scope. The scoped node files carry the current 2026-06-13 page date and 2026-06-12 discovery freshness.